Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?

Simply Wall St.08-25

AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2662208416?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285","is_english":true,"pubTime":"2026-08-25 00:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662208416","market":"sg","top_or_hot":-1,"title":"Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?","media":"Simply Wall St.","content":"<div>\n<p>AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvie-abbv-fairly-valued-as-new-lung-cancer-data-impress\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs AbbVie (ABBV) Fairly Valued As New Lung Cancer Data Impresses?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-25 00:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvie-abbv-fairly-valued-as-new-lung-cancer-data-impress><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvie-abbv-fairly-valued-as-new-lung-cancer-data-impress\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvie-abbv-fairly-valued-as-new-lung-cancer-data-impress","article_id":"2662208416","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/141885706-main-header/1756256222285"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/is-abbvie-abbv-fairly-valued-as-new-lung-cancer-data-impress","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662208416","pubTimestamp":1787588879,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates with manageable safety profiles.\nSee our latest analysis for AbbVie.\nThe latest lung cancer data arrives during a strong run for AbbVie, with a 24.32% 90 day share price return and a 31.62% 1 year total shareholder return suggesting that momentum has been building.\nIf this lung cancer update has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0861579265.USD":"联博低波幅策略股票基金A","IYH":"iShares U.S. Healthcare ETF","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","FHLC":"Fidelity MSCI Health Care Index","PPH":"VanEck Pharmaceutical ETF","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","PJP":"INVESCO PHARMACEUTICALS ETF","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","RXL":"ProShares Ultra Health Care","MEDX":"HORIZON KINETICS MEDICAL ETF","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","AGNG":"Global X Aging Population ETF","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4559":"巴菲特持仓","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","XLV":"健康照护类股ETF-SPDR","TRUH":"VanEck Healthcare TruSector ETF","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IXJ":"全球医疗业ETF-iShares","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2357627491.SGD":"TRP GLOBAL VALUE EQUITY \"AH\" (SGDHDG) ACC","VHT":"Vanguard Health Care ETF","LU2347655073.USD":"JPM GLOBAL INCOME \"A\" (USDHDG) INC A","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC"},"translate_title":"随着新的肺癌数据令人印象深刻，艾伯维 (ABBV) 的估值是否合理？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IYH":0.6,"PPH":0.6,"GLAM":0.6,"FHLC":0.6,"MEDX":0.6,"AGNG":0.6,"ABBV":1.5,"PJP":0.6,"FTXH":0.6,"RXL":0.6,"IXJ":0.6,"XLV":0.6,"TRUH":0.6,"JDOC":0.6,"VHT":0.6},"content_text":"AbbVie (ABBV) is back in focus after new lung cancer data at the 2026 World Conference on Lung Cancer, where its investigational therapies in both NSCLC and SCLC reported high objective response rates with manageable safety profiles. See our latest analysis for AbbVie. The latest lung cancer data arrives during a strong run for AbbVie, with a 24.32% 90 day share price return and a 31.62% 1 year total shareholder return suggesting that momentum has been building. If this lung cancer update has you looking more broadly at healthcare opportunities, it could be a good time to check out other potential growth stories through our screener of 41 healthcare AI stocks AbbVie’s lung cancer update arrives after a powerful run in the stock. The key issue now is whether recent gains have already priced in most of the opportunity, or if the current valuation still leaves clear upside on the table. AdvertisementMost Popular Narrative: 3.1% Undervalued AbbVie last closed at $264.96 compared with a widely followed fair value estimate of about $273 per share, which frames how some investors view the lung cancer data in the context of the broader story.  Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top line revenue growth and mitigate the impact of Humira's LOE.  Read the complete narrative. Want to see what really sits behind that fair value for AbbVie? The narrative leans on ambitious revenue expansion, rising margins and a richer earnings multiple. Curious which assumptions matter most? This widely followed framework uses a discount rate of 7.64% and ties AbbVie’s valuation to expectations around future growth in immunology, neuroscience and newer oncology assets. It also bakes in views on how long elevated profitability can be maintained as the portfolio shifts away from legacy products and as deals like Apogee are absorbed into the model. Result: Fair Value of $273.39 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear risks to the AbbVie story if newer therapies underperform in the clinic or if drug pricing reforms compress margins faster than expected. Find out about the key risks to this AbbVie narrative. Another View on AbbVie’s Valuation The fair value narrative for AbbVie leans on future earnings and multiples that could support the current share price. Yet on today’s numbers, the P/E ratio of 74.7x is well above the US Biotechs industry at 17.4x and peers at 29.1x, and is also higher than the 39.3x fair ratio estimate. That gap suggests investors are already paying a steep premium for AbbVie, which raises the risk that any disappointment in execution or lung cancer data could hit the share price harder than for cheaper stocks. The question is whether you think the current premium is justified, or if the market could move closer to that fair ratio over time. See what the numbers say about this price — find out in our valuation breakdown. NYSE:ABBV P/E Ratio as at Aug 2026Next Steps With AbbVie drawing such mixed reactions, it helps to move fast, review the underlying numbers yourself and then decide what really matters. To balance the optimism around rewards with the concerns about risks, start by checking the 3 key rewards and 4 important warning signs. Looking for more investment ideas beyond AbbVie? If AbbVie has sharpened your focus on where to put fresh capital next, consider scanning for other potential opportunities with clear, data driven filters.  Target resilient income by reviewing companies in the 12 dividend fortresses that aim to combine higher yields with consistency. Hunt for quality at a discount by reviewing the 48 high quality undervalued stocks and see which stocks currently trade below their fundamentals. Prioritize resilience and capital preservation by scanning the 75 resilient stocks with low risk scores so you are not the last to spot lower risk profiles.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662208416","isCrawlerRequest":true}